ClinicalTrials.gg
Enrolling by invitationNCT07448233Updated Nov 18, 2026

Application of Mini-Programs in Long-Term Management of Epilepsy in Rural Areas

An interventional study of WeChat mini-program "Epilepsy Smart Monitoring System" in Epilepsies and Remote Management of Epilepsy in Rural Areas, sponsored by Xijing Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Health services research

How we know

Updated Nov 18, 2026Study documents postedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Epilepsy with a site in China — 35 open to participants now, 41 under way, 5 of them phase 3. Epilepsy · China.

Planned enrollment
54th of 64
20 · median 141
Started
2025
with 8 others
No phase
21 of 101
9 open now
Primary completion
2028-11
later than 33 of 40 live
Registered
92nd of 101
by date
Lead sponsor
7 of 101
Xijing Hospital

Among the 101 studies in Epilepsy with a site in China, this one is the 54th largest by planned enrollment of the 64 interventional ones that give a count, is one of 9 that started in 2025, is one of 21 with no phase, reaches primary completion later than 33 of the 40 other live ones, and was the 92nd registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

35 of the 101 studies in Epilepsy with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Epilepsy with a site in China, or all of them as a file.
02

Study summary

This project, titled " Research on the Application of Mobile Health Management Mini-Programs in Long-Term Management of Epilepsy in Rural Areas", is led by the First Affiliated Hospital of Air Force Medical University, with Jiang Wen as the principal investigator. It is a prospective, multicenter, cluster-randomized controlled trial involving 1276 patients from eight rural counties in China's northwest region. This study aims to establish a new scheme for improving epilepsy management in rural areas of Northwest China by combining remote mobile health management technology. The primary objective is to evaluate the effectiveness of the remote medical management model using a mobile health management mini-program in improving the self-management ability of rural epilepsy patients; secondary objectives include evaluating the impact of this model on patients' medication adherence, quality of life, health status, and frequency of epileptic seizures. Key components include patient and doctor interfaces for features like medication reminders, and seizure records. The trial runs from December 1, 2025, to November 30, 2028, with primary outcomes measured at 6 and12 months and secondary outcomes assessing medication adherence, quality of life, and safety.

03

Conditions studied

  • Epilepsies
  • Remote Management of Epilepsy in Rural Areas

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient inclusion criteria:

  1. Meet the diagnostic criteria for epilepsy established by the International League Against Epilepsy (ILAE).
  2. Participate in the national rural epilepsy prevention and management project.
  3. Aged 18 to 64.
  4. The patient or their primary caregiver possesses a smartphone and is capable of using WeChat.
  5. Volunteer to participate in the study and sign a written form.

Patient exclusion criteria:

  1. Women who plan to become pregnant, are in pregnancy, or are breastfeeding.
  2. The seizures are caused by clear and reversible triggers.
  3. Those who have achieved epilepsy remission criteria and currently do not require long-term antiepileptic drug management.
  4. Severe infections, malignant tumors, severe dysfunction of heart, liver, and kidney functions, or severe physical diseases that the researcher believes will significantly affect epilepsy management, outcome evaluation, or follow-up completion.
  5. Individuals with severe mental, cognitive, or communication impairments who are unable to cooperate with research and remote management.
  6. It is expected that the participant will not be able to complete the required follow-up visits, or the investigator deems the participant unsuitable for participation in this study.
  7. Have participated in any other clinical trials within the past 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • No intervention
    Standard Rural Epilepsy Management
  • Experimental
    Enhanced Management with Mobile App

    Device: WeChat mini-program "Epilepsy Smart Monitoring System"

Interventions

  • DeviceWeChat mini-program "Epilepsy Smart Monitoring System"

    Patient Module: Real-time monitoring, medication reminders, seizure logging, educational resources. Physician Module: remote follow-up, data analytics dashboard.

06

What researchers measure

Primary outcomes

  1. Epilepsy Self Management Scale Score

    Evaluation method: The Chinese version of the Epilepsy Self Management Scale was used. This scale includes multiple dimensions (such as drug management, information management, safety management, etc.), and a higher total score indicates stronger self-management ability.

    Time frame: 6 and 12 months

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — IPD will not be shared due to privacy constraints, contractual agreements.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2028, 35 months after the start.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 35 months is below that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Nov 2027 → Nov 2028 and completion Nov 2027 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2025
First posted
Mar 4, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Nov 30, 2028was Nov 2027
CompletionEst.
Nov 30, 2028was Nov 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 30, 2027→Nov 30, 2028
Nov 18, 2026
Study completion
Nov 30, 2027→Nov 30, 2028
Nov 18, 2026
Eligibility
Maximum age 65 Years→64 Years; Criteria largely rewritten (22 changes)
What changed in the criteria
  • AddedPatient inclusion criteria:
  • AddedMeet the diagnostic criteria for epilepsy established by the International League Against Epilepsy (ILAE).
  • AddedParticipate in the national rural epilepsy prevention and management project.
  • EditedAged 18-65 years to 64.
  • AddedThe patient or their primary caregiver possesses a smartphone and is capable of using WeChat.
  • AddedVolunteer to participate in the study and sign a written informed consent form.
  • AddedPatient exclusion criteria:
  • AddedWomen who plan to become pregnant, are in pregnancy, or are breastfeeding.
  • AddedThe seizures are caused by clear and reversible triggers.
  • AddedThose who have achieved epilepsy remission criteria and currently do not require long-term antiepileptic drug management.
  • AddedSevere infections, malignant tumors, severe dysfunction of heart, liver, and kidney functions, or severe physical diseases that the researcher believes will significantly affect epilepsy management, outcome evaluation, or follow-up completion.
  • AddedIndividuals with severe mental, cognitive, or communication impairments who are unable to cooperate with research and remote management.
  • AddedIt is expected that the participant will not be able to complete the required follow-up visits, or the investigator deems the participant unsuitable for participation in this study.
  • AddedHave participated in any other clinical trials within the past 6 months.
Inclusion criteria
  • RemovedMeets ILAE 2017 diagnostic criteria for epilepsy.
  • Removed≥1 bilateral tonic-clonic seizure in the past 12 months.
  • RemovedAccess to a smartphone patient/caregiver.
  • RemovedWritten informed consent.
Exclusion criteria
  • RemovedPregnancy, lactation, or planned pregnancy.
  • RemovedSeizures with identifiable triggers e.g., alcohol withdrawal.
  • RemovedAllergy to phenobarbital/sodium valproate.
  • RemovedSevere comorbidities e.g., organ dysfunction, malignancy, psychiatric disorders.
Nov 18, 2026
Interventions
Changed AI-enabled WeChat mini-program "Epilepsy Smart Monitoring and Diagnosis System":→WeChat mini-program "Epilepsy Smart Monitoring System"
Nov 18, 2026
Primary outcomes
1 time frame changed, 1 removed
What changed in the outcomes
  • RemovedSeizure changeTime frame: 12 months
  • Time frameEpilepsy Self Management Scale Score12 months → 6 and 12 months
Nov 18, 2026
Documents
Nov 18, 2026
Title
Application of an AIMini-Based Health Management SystemPrograms in Long-Term Management of Epilepsy Management in Rural Areas
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Documents Study protocol ↗ updated
    Primary completion Nov 30, 2027→Nov 30, 2028
    Study completion Nov 30, 2027→Nov 30, 2028
    Eligibility Maximum age 65 Years→64 Years; Criteria largely rewritten (22 changes)
    What changed in the criteria
    • AddedPatient inclusion criteria:
    • AddedMeet the diagnostic criteria for epilepsy established by the International League Against Epilepsy (ILAE).
    • AddedParticipate in the national rural epilepsy prevention and management project.
    • EditedAged 18-65 years to 64.
    • AddedThe patient or their primary caregiver possesses a smartphone and is capable of using WeChat.
    • AddedVolunteer to participate in the study and sign a written informed consent form.
    • AddedPatient exclusion criteria:
    • AddedWomen who plan to become pregnant, are in pregnancy, or are breastfeeding.
    • AddedThe seizures are caused by clear and reversible triggers.
    • AddedThose who have achieved epilepsy remission criteria and currently do not require long-term antiepileptic drug management.
    • AddedSevere infections, malignant tumors, severe dysfunction of heart, liver, and kidney functions, or severe physical diseases that the researcher believes will significantly affect epilepsy management, outcome evaluation, or follow-up completion.
    • AddedIndividuals with severe mental, cognitive, or communication impairments who are unable to cooperate with research and remote management.
    • AddedIt is expected that the participant will not be able to complete the required follow-up visits, or the investigator deems the participant unsuitable for participation in this study.
    • AddedHave participated in any other clinical trials within the past 6 months.
    Inclusion criteria
    • RemovedMeets ILAE 2017 diagnostic criteria for epilepsy.
    • Removed≥1 bilateral tonic-clonic seizure in the past 12 months.
    • RemovedAccess to a smartphone patient/caregiver.
    • RemovedWritten informed consent.
    Exclusion criteria
    • RemovedPregnancy, lactation, or planned pregnancy.
    • RemovedSeizures with identifiable triggers e.g., alcohol withdrawal.
    • RemovedAllergy to phenobarbital/sodium valproate.
    • RemovedSevere comorbidities e.g., organ dysfunction, malignancy, psychiatric disorders.
    Primary outcomes 1 time frame changed, 1 removed
    What changed in the outcomes
    • RemovedSeizure changeTime frame: 12 months
    • Time frameEpilepsy Self Management Scale Score12 months → 6 and 12 months
    Interventions Changed AI-enabled WeChat mini-program "Epilepsy Smart Monitoring and Diagnosis System":→WeChat mini-program "Epilepsy Smart Monitoring System"
    Title Application of an AIMini-Based Health Management SystemPrograms in Long-Term Management of Epilepsy Management in Rural Areas
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07448233
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Dec 1, 2025
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion